{
  "symbol": "CYTK",
  "company": "Cytokinetics, Incorporated",
  "generated_at": "2026-06-24T07:36:46.989Z",
  "event_count": 3,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-06-02T00:46:24.004Z",
      "stage": "analyst",
      "outcome": "skip",
      "reason": "Material insider selling, pre-profitability burn, and dilution overhang at all-time highs leave no clear asymmetric or mispriced setup; the active anti-signals (dilution, going concern, high burn) and lack of fundamental edge justify a skip.",
      "trigger": "[insider_cluster_universe] 3 Form 4 filings in last 14 days · at least one open-market P/S trade verified",
      "source": "idle_hunter"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-06-02T00:46:23.982Z",
      "skip": true,
      "reason": "Material insider selling, pre-profitability burn, and dilution overhang at all-time highs leave no clear asymmetric or mispriced setup; the active anti-signals (dilution, going concern, high burn) and lack of fundamental edge justify a skip.",
      "score": 22,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 0,
        "catalyst": 13,
        "mispricing": 0,
        "quality": 0,
        "technical": 9
      },
      "debug_path": "drafts/2026-06-02-CYTK.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-02T00:45:53.806Z",
      "summary": "Cytokinetics has a commercial product (MYQORZO/aficamten) newly launched in Q1 2026 following FDA approval Dec 2025 and EU launch June 2026. The stock is near all-time highs at $73.68 (52w high $80.20), up ~152% over 1 year, on strong MYQORZO early commercial traction. Insider Form 4 filings are extremely active in the last 14 days but ALL transactions reviewed were SELLs by directors and employees (exercise of options + immediate sale) — no open-market P/S purchases verified despite the cluster trigger. CEO Blum sold $446K on 04/29, EVP Malik exercised options and sold ~$270K on 05/05, Director Kaye sold $223K on 06/01, Director Parshall sold $370K on 06/01 — all at various price points. This is a high-quality company with real product traction but the stock is fully-valued (no forward PE given pre-profitability; EV/EBITDA N/A) and near its 52w ceiling. The insider cluster reflects compensation-related exercise-and-sell activity, not conviction buying.",
      "verdict": "range_bound_or_income",
      "confidence": 5,
      "tool_calls": 20,
      "walltime_min": 26,
      "debug_path": "dossiers/2026-06-02-CYTK.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "CYTK",
    "call": "BUY",
    "confidence": 5,
    "score": 8,
    "factors": {
      "above_200dma": "+2",
      "above_50dma": "+1",
      "momentum_strong_up": "+2 (133.7%)",
      "rsi_neutral": "0 (65.9)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (3d ago)",
      "near_52w_high": "+1 (0.0% from high)"
    },
    "summary": "BUY (score +8) · 12-1 mom 133.7% · RSI 65.9 · above_both · 0.0% from high",
    "last_close": 80.01,
    "one_month_ago_close": 78.06,
    "twelve_month_ago_close": 33.4,
    "twelve_one_momentum_pct": 133.71,
    "rsi_14": 65.9,
    "ma_stack": "above_both",
    "from_period_high_pct": 0,
    "period_high": 80.01,
    "price_targets": {
      "bear": 56.01,
      "fair": 85.71,
      "bull": 146,
      "bear_return_pct": -30,
      "fair_return_pct": 7.1,
      "bull_return_pct": 82.5,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 69,
        "target_mean": 105.6,
        "target_high": 146,
        "analyst_count": 20
      }
    },
    "generated_at": "2026-06-24T07:36:46.985Z"
  }
}